Transcutaneous penetration of a single-chain variable fragment (scFv) compared to a full-size antibody: potential tool for atopic dermatitis (AD) treatment.
Antibody
Atopic dermatitis
Single-chain variable fragment
Transcutaneous penetration
Journal
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
ISSN: 1710-1484
Titre abrégé: Allergy Asthma Clin Immunol
Pays: England
ID NLM: 101244313
Informations de publication
Date de publication:
19 Jul 2021
19 Jul 2021
Historique:
received:
03
05
2021
accepted:
28
06
2021
entrez:
20
7
2021
pubmed:
21
7
2021
medline:
21
7
2021
Statut:
epublish
Résumé
Currently, several biologics are used for the treatment of cutaneous pathologies such as atopic dermatitis (AD), psoriasis or skin cancers. The main administration routes are subcutaneous and intravenous injections. However, little is known about antibody penetration through the skin. The aim was to study the transcutaneous penetration of a reduced-size antibody as a single-chain variable fragment (scFv) compared to a whole antibody (Ab) and to determine its capacity to neutralize an inflammatory cytokine involved in AD such as human interleukin-4 (hIL-4). Transcutaneous penetration was evaluated by ex vivo studies on tape-stripped pig ear skin. ScFv and Ab visualization through the skin was measured by Raman microspectroscopy. In addition, hIL-4 neutralization was studied in vitro using HEK-Blue™ IL-4/IL-13 cells and normal human keratinocytes (NHKs). After 24 h of application, analysis by Raman microspectroscopy showed that scFv penetrated into the upper dermis while Ab remained on the stratum corneum. In addition, the anti-hIL4 scFv showed very efficient and dose-dependent hIL-4 neutralization. Thus, scFv penetrates through to the upper papillary dermis while Ab mostly remains on the surface, the anti-hIL4 scFv also neutralizes its target effectively suggesting its potential use as topical therapy for AD.
Identifiants
pubmed: 34281610
doi: 10.1186/s13223-021-00574-x
pii: 10.1186/s13223-021-00574-x
pmc: PMC8290589
doi:
Types de publication
Journal Article
Langues
eng
Pagination
73Informations de copyright
© 2021. The Author(s).
Références
Clin Rev Allergy Immunol. 2011 Dec;41(3):298-310
pubmed: 21249468
J Invest Dermatol. 1998 Apr;110(4):393-8
pubmed: 9540981
Antibodies (Basel). 2018 Jul 07;7(3):
pubmed: 31544876
Clin Rev Allergy Immunol. 2014 Oct;47(2):193-218
pubmed: 24715253
J Invest Dermatol. 2013 Apr;133(4):1008-16
pubmed: 23223144
Anticancer Agents Med Chem. 2017;17(2):301-308
pubmed: 27225449
J Allergy Clin Immunol. 2019 Jan;143(1):155-172
pubmed: 30194992
Onco Targets Ther. 2018 Sep 25;11:6177-6187
pubmed: 30288053
Ann Nutr Metab. 2015;66 Suppl 1:8-16
pubmed: 25925336
J Am Acad Dermatol. 2019 Jul;81(1):196-203
pubmed: 30926369
Nano Lett. 2016 Apr 13;16(4):2334-40
pubmed: 26999507
Sci Rep. 2018 Aug 9;8(1):11895
pubmed: 30093649
Drug Discov Today. 2021 Jan;26(1):248-255
pubmed: 33137480
Colloids Surf B Biointerfaces. 2017 Nov 1;159:23-29
pubmed: 28779637
Anal Chem. 2020 Aug 4;92(15):10381-10389
pubmed: 32614170
Int Wound J. 2006 Sep;3(3):171-9
pubmed: 16984574
J Pharm Sci. 2017 Jul;106(7):1795-1804
pubmed: 28336300
J Pharm Sci. 2004 Apr;93(4):1005-18
pubmed: 14999736
J Eur Acad Dermatol Venereol. 2020 Dec;34 Suppl 7:3-18
pubmed: 33315305